Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18808126 | ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) METHOD AND MONOCLONAL ANTIBODY FOR GIANT PANDA RELAXIN-3 (RLN3) | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18395108 | ANTIBODY THAT BINDS LPAR1 | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18509397 | COMPOSITIONS AND METHODS FOR REPAIRING CARTILAGE DEFECTS | November 2023 | August 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18508874 | ANTI-PAPP-A ANTIBODIES AND METHODS OF USE THEREOF | November 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18488265 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION | October 2023 | June 2025 | Allow | 20 | 1 | 1 | No | No |
| 18485116 | TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS | October 2023 | June 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18366770 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT | August 2023 | June 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18364173 | MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR TREATING CANCER CACHEXIA AND CANCER | August 2023 | September 2025 | Abandon | 26 | 2 | 0 | No | No |
| 18336713 | ANTI-GDF-15 ANTIBODIES | June 2023 | November 2024 | Allow | 17 | 2 | 0 | No | No |
| 18333425 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization | June 2023 | December 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18318336 | THERAPY FOR GLAUCOMA AND OPTIC NEUROPATHY BY TARGETING COLONY STIMULATING FACTORS | May 2023 | October 2024 | Allow | 17 | 1 | 1 | No | No |
| 18312879 | METHOD RELATING TO MYOSTATIN PATHWAY INHIBITION | May 2023 | April 2025 | Abandon | 24 | 2 | 1 | Yes | No |
| 18307920 | COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE (SEMA4D) AND DC1 THERAPY | April 2023 | September 2024 | Allow | 17 | 1 | 1 | No | No |
| 18024879 | hAM15-52 ANALOGUES WITH IMPROVED AMYLIN RECEPTOR (hAMY3R) POTENCY | March 2023 | July 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18175409 | ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION | February 2023 | August 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18070407 | Compositions and Methods of Use for Recombinant Human Secretoglobins | November 2022 | September 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17982390 | Compositions and Methods of Use for Treating Metabolic Disorders | November 2022 | August 2024 | Allow | 21 | 1 | 1 | No | No |
| 17921810 | ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION | October 2022 | July 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17960911 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION | October 2022 | October 2024 | Allow | 25 | 2 | 0 | No | No |
| 17907653 | STEM CELL-DERIVED EXOSOMES CONTAINING PAIN REGULATORS, AND USES THEREOF | September 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17912913 | PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISORDER, COMPRISING MESENCHYMAL STEM CELLS OR INSULIN SECRETED BY MESENCHYMAL STEM CELLS | September 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17948814 | ANTIBODY VARIANTS | September 2022 | June 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17930389 | METABOLIC BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND | September 2022 | March 2025 | Allow | 30 | 3 | 0 | No | No |
| 17905572 | PRIMER SETS FOR DETECTION OF MYCOPLASMA PNEUMONIAE BACTERIA, METHOD FOR DETECTION OF MYCOPLASMA PNEUMOANIAE INFECTION, USE OF A PRIMER SET FOR DETECTION OF MYCOPLASMA PNEUMONIAE INFECTION | September 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17929261 | INFLAMMATORY BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND | September 2022 | March 2025 | Allow | 30 | 2 | 1 | No | No |
| 17816484 | ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | August 2022 | October 2024 | Allow | 26 | 2 | 1 | No | No |
| 17815681 | METHOD OF DETERMINING THE IDENTITY AND/OR AMOUNT OF AN ANTI-IL-31 ANTIBODY IN A SAMPLE | July 2022 | February 2025 | Allow | 31 | 1 | 1 | No | No |
| 17856944 | PROCESSES FOR MAKING A CELLULAR FIBRONECTIN COMPOSITION | July 2022 | August 2024 | Allow | 26 | 1 | 1 | No | No |
| 17787168 | IL-37 FUSION PROTEINS AND USES THEREOF | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17774383 | TREATMENTS FOR SYSTEMIC SCLEROSIS | May 2022 | September 2025 | Allow | 41 | 1 | 0 | No | No |
| 17668456 | Biomarker of Gingivitis Diagnosis and Treatment | February 2022 | November 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17633764 | MODULATORS OF PARATHYROID HORMONE RECEPTOR (PTHR1) | February 2022 | May 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17578792 | VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR | January 2022 | October 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17625460 | NOVEL IL-10 VARIANT PROTEIN AND USE THEREOF | January 2022 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17558826 | EXTENDED RELEASE IMMUNOMODULATORY IMPLANT TO FACILITATE BONE MORPHOGENESIS | December 2021 | August 2025 | Allow | 44 | 1 | 1 | No | No |
| 17547069 | Methods for Treating Osteogenesis Imperfecta | December 2021 | March 2025 | Allow | 39 | 3 | 0 | Yes | No |
| 17463664 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED CARDIOMETABOLIC DISEASES | September 2021 | December 2024 | Abandon | 39 | 3 | 0 | No | No |
| 17394238 | METHODS FOR DETECTING METEORIN-BETA ACTIVITY | August 2021 | July 2025 | Allow | 47 | 3 | 1 | No | No |
| 17312884 | ANTI PD-L1 ANTIBODY AND USE THEREOF | June 2021 | May 2025 | Allow | 47 | 2 | 0 | No | No |
| 17057499 | METHOD FOR DIAGNOSING INFECTION WITH HELICOBACTER SUIS | June 2021 | December 2024 | Abandon | 48 | 0 | 1 | No | No |
| 17299211 | CANCER REGRESSION BY INDUCING A REGENERATION-LIKE RESPONSE | June 2021 | January 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17299156 | ANTI-TM4SF4 ANTIBODY AND USES THEREOF | June 2021 | May 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17335291 | RABBIT ANTIBODIES TO HUMAN IMMUNOGLOBULINS G | June 2021 | September 2024 | Allow | 40 | 1 | 1 | No | No |
| 17326725 | HIGH CONCENTRATION ANTIBODY FORMULATIONS | May 2021 | August 2024 | Allow | 39 | 2 | 1 | No | No |
| 17283553 | NOVEL ANTI-CD39 ANTIBODIES | April 2021 | March 2025 | Allow | 48 | 2 | 1 | No | No |
| 17281874 | ANTIBODIES AND USES THEREOF | March 2021 | October 2024 | Allow | 42 | 1 | 1 | No | No |
| 17281464 | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS | March 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17210037 | METHODS AND COMPOSITIONS FOR TREATING MYELOFIBROSIS | March 2021 | September 2024 | Allow | 41 | 3 | 0 | No | No |
| 17274457 | MARKERS USEFUL IN ENRICHMENT STRATEGIES FOR THE TREATMENT OF OSTEOARTHRITIS | March 2021 | April 2025 | Allow | 49 | 4 | 1 | Yes | No |
| 17194144 | BINDING PROTEINS AND METHODS OF USE THEREOF | March 2021 | August 2024 | Allow | 41 | 3 | 1 | No | No |
| 17187168 | USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA | February 2021 | January 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17165011 | COMPOSITIONS AND METHODS FOR SUPPORTING NUCLEUS PULPOSUS (NP) CELL PHENOTYPE AND BIOSYNTHESIS | February 2021 | September 2024 | Allow | 44 | 4 | 1 | No | No |
| 17262579 | IMPROVED WEIGHT LOSS THERAPY | January 2021 | March 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17261314 | COMPOSITIONS FOR THE TREATMENT OF SARCOPENIA OR DISUSE ATROPHY | January 2021 | August 2025 | Allow | 54 | 3 | 1 | No | Yes |
| 17053600 | Epitope of Regulatory T Cell surface Antigen and Antibody Specifically Biding Thereto | November 2020 | April 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17046509 | ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | October 2020 | October 2024 | Allow | 48 | 2 | 1 | No | No |
| 16956036 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND MIDREGIONAL-PROADRENOMEDULLIN | June 2020 | September 2023 | Abandon | 39 | 3 | 0 | Yes | No |
| 16765060 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF | May 2020 | October 2024 | Allow | 53 | 4 | 1 | No | No |
| 16755090 | METHODS FOR MONITORING VEDOLIZUMAB TREATMENT | April 2020 | October 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16497105 | METHODS AND COMPOSITIONS FOR REGULATING INNATE LYMPHOID CELL INFLAMMATORY RESPONSES | September 2019 | July 2024 | Allow | 58 | 5 | 1 | Yes | No |
| 16539455 | METHODS FOR TREATING IL-31-MEDIATED CONDITIONS IN COMPANION ANIMALS | August 2019 | August 2025 | Abandon | 60 | 6 | 0 | No | Yes |
| 16475570 | METHODS FOR SCAR REDUCTION BY CONVERTING SCAR FIBROBLASTS INTO ADIPOCYTES WITH HAIR FOLLICLE-DERIVED SIGNALS | July 2019 | June 2024 | Allow | 59 | 5 | 1 | No | No |
| 15765207 | COMBINATION OF AN IL-2RBETA-SELECTIVE AGONIST AND A LONG-ACTING IL-15 AGONIST | March 2018 | October 2024 | Allow | 60 | 5 | 1 | No | Yes |
| 15844526 | ANTIBODY TO GDF8 AND USES THEREOF | December 2017 | August 2018 | Allow | 8 | 0 | 0 | No | No |
| 15839372 | CRYPTIC POLYPEPTIDES AND USES THEREOF | December 2017 | February 2019 | Allow | 14 | 2 | 0 | Yes | No |
| 15789753 | Compositions and methods of use for treating metabolic disorders | October 2017 | July 2019 | Allow | 21 | 1 | 1 | No | No |
| 15336155 | STABLE MIA/CD-RAP FORMULATION | October 2016 | October 2017 | Allow | 12 | 2 | 0 | No | No |
| 15230430 | ANTIBODY TO GDF8 AND USES THEREOF | August 2016 | May 2017 | Allow | 9 | 0 | 0 | No | No |
| 14917757 | KITS FOR CLASSIFYING A SUBJECT HAVING OR AT RISK FOR DEVELOPING IDIOPATHIC SCOLIOSIS | March 2016 | November 2018 | Allow | 32 | 3 | 1 | Yes | No |
| 14996483 | BIORESORBABLE WOUND DRESSING | January 2016 | July 2017 | Allow | 18 | 2 | 0 | Yes | No |
| 14944357 | METHOD FOR REGENERATING CARTILAGE COMPRISING APPLYING A MONOVALENT METAL SALT OF ALGINIC ACID AND SDF-1 | November 2015 | July 2017 | Allow | 20 | 2 | 0 | Yes | No |
| 14832017 | Extracellular Matrix Constructs for Treating Damaged Biological Tissue | August 2015 | March 2017 | Allow | 19 | 2 | 0 | No | No |
| 14800770 | OSTEOGENIC REGENERATIVE SCAFFOLD MATRIX COMPOSITION | July 2015 | March 2017 | Allow | 20 | 1 | 1 | Yes | No |
| 14495424 | METHODS FOR BINDING MEMBERS OF INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ra) | September 2014 | October 2016 | Allow | 25 | 1 | 1 | Yes | No |
| 14473186 | HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | August 2014 | November 2016 | Allow | 26 | 2 | 1 | Yes | No |
| 14316137 | BMP-6 Antibodies and DNA Encoding the Same | June 2014 | November 2014 | Allow | 5 | 1 | 0 | No | No |
| 14241939 | COMPOSITION FOR IMPROVING SKIN CONDITIONS, CONTAINING EXTRACELLULAR DOMAIN OF HUMAN BONE MORPHOGENETIC PROTEIN RECEPTOR 1a AS ACTIVE INGREDIENT | June 2014 | May 2016 | Allow | 26 | 2 | 0 | No | No |
| 14282319 | PD-1 ANTIBODIES AND PD-L1 ANTIBODIES AND USES THEREOF | May 2014 | December 2016 | Allow | 31 | 4 | 0 | No | No |
| 14124187 | METHODS FOR REPAIRING TISSUE DAMAGE USING PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 | January 2014 | September 2019 | Allow | 60 | 6 | 1 | No | No |
| 14128185 | BIORESORBABLE WOUND DRESSING | December 2013 | November 2015 | Allow | 22 | 2 | 1 | Yes | No |
| 14097335 | BMP-6 Antibodies | December 2013 | May 2014 | Allow | 6 | 1 | 0 | No | No |
| 13981697 | ANTI-TACE ANTIBODY MOLECULES AND THEIR USES | September 2013 | June 2015 | Allow | 22 | 2 | 1 | No | No |
| 14012626 | ANTIBODIES THAT SPECIFICALLY BIND SOST AND WISE PEPTIDES | August 2013 | December 2015 | Allow | 28 | 0 | 2 | Yes | No |
| 13877779 | ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15 | July 2013 | May 2015 | Allow | 25 | 1 | 1 | Yes | No |
| 13916379 | ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES THEREFOR | June 2013 | November 2014 | Allow | 17 | 1 | 1 | No | No |
| 13911256 | Binding members for interleukin-4 receptor alpha (IL-4Ra) - 173 | June 2013 | June 2014 | Allow | 13 | 1 | 1 | No | No |
| 13863343 | BNP-SP ANTIBODIES | April 2013 | September 2015 | Allow | 29 | 2 | 1 | No | No |
| 13791700 | ANTIBODY TO GDF8 AND USES THEREOF | March 2013 | March 2015 | Allow | 24 | 1 | 1 | Yes | No |
| 13788517 | PROTEIN STABILIZATION FORMULATIONS | March 2013 | January 2014 | Allow | 10 | 1 | 0 | No | No |
| 13781070 | Methods of Preventing Ischemia/Reperfusion Damage to Kidney Using Antibodies that Bind BMP-1 Isoforms | February 2013 | February 2014 | Allow | 11 | 1 | 1 | Yes | No |
| 13699288 | Compositions Comprising spp24 Peptide Fragments | February 2013 | October 2014 | Allow | 22 | 2 | 1 | Yes | No |
| 13758950 | USE OF HISTONES FOR THERAPEUTIC PURPOSES | February 2013 | July 2014 | Allow | 17 | 1 | 0 | Yes | No |
| 13721513 | METHOD FOR INDUCING TISSUE GROWTH, DIFFERENTIATION AND/OR REGENERATION BY DELIVERING A GDF-5 RELATED PRECURSOR PROTEIN | December 2012 | July 2014 | Allow | 19 | 1 | 1 | Yes | No |
| 13691395 | NEUTRALIZING ANTIBODIES AGAINST GDF-8 AND USES THEREFOR | November 2012 | August 2014 | Allow | 21 | 1 | 1 | No | No |
| 13682580 | MYOSTATIN BINDING AGENTS, NUCLEIC ACIDS ENCODING THE SAME, AND METHODS OF TREATMENT | November 2012 | July 2014 | Allow | 20 | 2 | 1 | Yes | No |
| 13659647 | IMMUNOBINDERS DIRECTED AGAINST SCLEROSTIN | October 2012 | November 2014 | Allow | 25 | 2 | 1 | Yes | Yes |
| 13512780 | HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | September 2012 | May 2014 | Allow | 24 | 1 | 1 | No | No |
| 13572141 | COMPOSITIONS AND METHODS FOR TREATING BONE CONDITIONS | August 2012 | November 2015 | Allow | 39 | 3 | 1 | No | No |
| 13514362 | BLACK BEAR PARATHYROID HORMONE AND METHODS OF USING BLACK BEAR PARATHYROID HORMONE | June 2012 | February 2014 | Allow | 20 | 2 | 1 | No | No |
| 13478556 | METHOD FOR INHIBITING BONE RESORPTION | May 2012 | March 2013 | Allow | 9 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KEMMERER, ELIZABETH.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner KEMMERER, ELIZABETH works in Art Unit 1674 and has examined 235 patent applications in our dataset. With an allowance rate of 95.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner KEMMERER, ELIZABETH's allowance rate of 95.7% places them in the 85% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by KEMMERER, ELIZABETH receive 1.91 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KEMMERER, ELIZABETH is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +2.4% benefit to allowance rate for applications examined by KEMMERER, ELIZABETH. This interview benefit is in the 23% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 25.4% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 62.2% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 88.5% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 87.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 65.5% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 19.6% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.